Shares of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) have been assigned a consensus recommendation of “Hold” from the nine research firms that are presently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and one has issued a buy rating on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $7.00.
Several equities analysts have weighed in on the company. ValuEngine upgraded Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, August 1st. BidaskClub cut Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, August 8th. Stifel Nicolaus cut their price target on Keryx Biopharmaceuticals from $7.00 to $5.00 and set a “hold” rating for the company in a report on Wednesday, November 8th. Maxim Group set a $9.00 price target on Keryx Biopharmaceuticals and gave the company a “buy” rating in a report on Thursday, July 27th. Finally, Zacks Investment Research cut Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, November 10th.
COPYRIGHT VIOLATION WARNING: “Brokerages Set Keryx Biopharmaceuticals, Inc. (KERX) PT at $7.00” was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://ledgergazette.com/2017/11/16/brokerages-set-keryx-biopharmaceuticals-inc-kerx-pt-at-7-00.html.
Institutional investors have recently made changes to their positions in the company. Fox Run Management L.L.C. purchased a new position in shares of Keryx Biopharmaceuticals in the 3rd quarter worth approximately $101,000. Engineers Gate Manager LP purchased a new position in shares of Keryx Biopharmaceuticals in the 3rd quarter worth approximately $102,000. Principal Financial Group Inc. boosted its holdings in shares of Keryx Biopharmaceuticals by 4.2% in the 2nd quarter. Principal Financial Group Inc. now owns 14,759 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 590 shares during the period. Raymond James Financial Services Advisors Inc. boosted its holdings in shares of Keryx Biopharmaceuticals by 51.8% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 16,495 shares of the biopharmaceutical company’s stock worth $119,000 after purchasing an additional 5,628 shares during the period. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of Keryx Biopharmaceuticals in the 2nd quarter worth approximately $183,000. Hedge funds and other institutional investors own 65.44% of the company’s stock.
Keryx Biopharmaceuticals (NASDAQ KERX) traded down $0.16 during trading hours on Monday, hitting $4.87. The company had a trading volume of 2,827,488 shares, compared to its average volume of 1,519,990. The company has a debt-to-equity ratio of 13.95, a current ratio of 4.46 and a quick ratio of 3.76. Keryx Biopharmaceuticals has a 12-month low of $4.47 and a 12-month high of $8.38.
Keryx Biopharmaceuticals (NASDAQ:KERX) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.03). The firm had revenue of $15.00 million for the quarter, compared to analysts’ expectations of $18.88 million. Keryx Biopharmaceuticals had a negative net margin of 323.92% and a negative return on equity of 10,954.62%. The business’s quarterly revenue was up 138.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.39) EPS. research analysts anticipate that Keryx Biopharmaceuticals will post -1.36 EPS for the current year.
About Keryx Biopharmaceuticals
Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.
Receive News & Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.